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ABSTRACT Ebola and Marburg viruses can cause
hemorrhagic fever (HF) outbreaks with high mortality
in primates. Whereas Marburg (MARV), Ebola Zaire
(ZEBOV), and Ebola Sudan (SEBOV) viruses are patho-
genic in humans, apes, and monkeys, Ebola Reston
(REBOV) is pathogenic only in monkeys (1–3). Early
immunosuppression may contribute to pathogenesis by
facilitating viral replication (4–6). Lymphocyte deple-
tion, intravascular apoptosis, and cytokine dysregula-
tion are prominent in fatal cases (7). Here we function-
ally characterize a 17 amino acid domain in filoviral
glycoproteins that resembles an immunosuppressive
motif in retroviral envelope proteins (8, 9). Activated
human or rhesus peripheral blood mononuclear cells
(PBMC) were exposed to inactivated ZEBOV or a panel
of 17mer peptides representing all sequenced strains of
filoviruses, then analyzed for CD4 and CD8 T cell
activation, apoptosis, and cytokine expression. Expo-
sure of human and rhesus PBMC to ZEBOV, SEBOV,
or MARV peptides or inactivated ZEBOV resulted in
decreased expression of activation markers on CD4
and CD8 cells; CD4 and CD8 cell apoptosis as early as
12 h postexposure; inhibition of CD4 and CD8 cell
cycle progression; decreased interleukin (IL)-2, IFN-,
and IL12-p40 expression; and increased IL-10 expres-
sion. In contrast, only rhesus T cells were sensitive to
REBOV peptides. These findings are consistent with
the observation that REBOV is not pathogenic in hu-
mans and have implications for understanding the
pathogenesis of filoviral HF.—Yaddanapudi, K., Pala-
cios, G., Towner, J. S., Chen, I., Sariol, C. A., Nichol,
S. T., Lipkin, W. I. Implication of a retrovirus-like
glycoprotein peptide in the immunopathogenesis of
Ebola and Marburg viruses. FASEB J. 20, 2519–2530
(2006)
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The filoviruses cause hemorrhagic fevers with high
levels of fatality. They are classified in two genera within
the family Filoviridae: Ebola virus (EBOV) and Marburg
virus (MARV). Four species of Ebola virus are currently
recognized: Zaire, Sudan, Reston, and Ivory Coast. Ebola
virus species Zaire (ZEBOV) and Sudan (SEBOV) as well
as Marburg (MARV) are highly pathogenic in human
and nonhuman primates, with case fatality levels of up
to 90%. Ebola virus species Reston (REBOV) is patho-
genic in monkeys but does not cause disease in humans
or great apes (1–3). Fatal outcome in filoviral infection
is associated with an early reduction in the number of
circulating T cells, failure to develop specific humoral
immunity, and the release of proinflammatory cyto-
kines (7, 10, 11). The membrane-anchored filoviral
glycoprotein (GP) is present on the surface of virions
and infected cells; GP mediates receptor binding and
fusion. Filoviral GPs are considered to be major viral
pathogenic determinants and contribute to both immu-
nosuppression and vascular dysregulation (12–14).
The transmembrane glycoproteins of many animal
and human retroviruses share structural features, in-
cluding a conserved region that has strong immuno-
suppressive properties (15, 16). CKS17, a synthetic
peptide corresponding to this domain in oncogenic
retroviruses, has been used to dissect the pathophysiol-
ogy of immunosuppression (17, 18). CKS17 causes an
imbalance of human type-1 and type-2 cytokine produc-
tion, suppresses cell-mediated immunity (19), and
blocks the activity of protein kinase C, a cellular mes-
senger involved in T cell activation (20, 21). During the
course of establishing a microbial sequence database to
support development of tools for surveillance and
differential diagnosis of infectious diseases, we discov-
ered a region of strong secondary structure conserva-
tion between the C-terminal domain of the envelope
glycoprotein of filoviruses and CKS17 (Supplemental
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Fig. 1). An alignment of the filoviral glycoprotein and
retroviral immunosuppressive domains illustrated pri-
mary sequence similarity between a wide range of
retroviruses and filoviruses. Three cysteine residues
implicated in disulfide bonding were also conserved,
reinforcing similarities at the level of secondary struc-
ture. Here we report functional analysis of the putative
immunosuppressive domain in various species of EBOV
and MARV and demonstrate that the immunosuppres-
sive effect of different species of GP peptides is consis-
tent with pathogenicity observed in different animal
hosts.
MATERIALS AND METHODS
Design of the synthetic peptides
Filoviral 17-mer peptides corresponding to the immunosup-
pressive domain were synthesized at the Northeast Biodefense
Center Proteomics Core-Keck Laboratory, Yale University.
Identification of the region with strong secondary structure
similarity to the retrovirus glycoprotein was done using the
program 3D-PSSM (22) (Supplemental Fig. 1). The ZEBOV
peptide is ILNRKAIDFLLQRWGGT. ZEBOV and SEBOV
differ by one residue at position 12 (ZEBOV, glutamine;
SEBOV, arginine); both have isoleucine at position 1. REBOV
differs from ZEBOV only in the presence of leucine at
position 1.
Cell culture
Human PBMC were isolated from heparinized venous blood
of healthy volunteers by density gradient centrifugation over
Ficoll-Hypaque (Amersham Biosciences, Piscataway, NJ,
USA). Monkey PBMC were separated from heparin-treated
peripheral blood collected from healthy adult rhesus (Macaca
mulatta) macaques using a similar procedure. Human PBMC
were suspended at 106/ml in RPMI 1640 supplemented with
10% FBS (Irvine Scientific, Santa Ana, CA, USA) and cultured
in the presence of soluble anti-human CD28 at 2 g/ml on
plates coated with anti-human CD3 antibody (Ab) at 10
g/ml (anti-CD3/CD28) alone (23); anti-CD3/CD28 and
inactivated ZEBOV (inactZEBOV; equivalent of 25 infectious
units per cell prior to -irradiation using 5106 rads); or
anti-CD3/CD28 and filoviral peptides at 40 M concentra-
tion. Cells were incubated at 37°C in 5% C02 for 12 or 48 h
prior to analysis. Conditions were similar for experiments
with rhesus PBMC except that cells were activated by culture
on plates coated with anti-human CD3 epsilon Ab (anti-CD3ε,
clone: SP34, cross-reactive with rhesus CD3) (24) at 10
g/ml.
Cell surface phenotype
All monoclonal antibodies (mAbs) used in FACS analyses
were generated using human antigens; some were human-
specific (Caltag): Anti-CD4-APC (clone: S3.5, isotype: mouse
IgG2a), anti-CD8-APC (clone: 3B5, isotype: mouse IgG2a),
anti-CD25-FITC (clone: CD25–3G10, isotype: mouse IgG1),
anti-CD4-PE (clone: S3.5, isotype: mouse IgG2a) and anti-
CD69-FITC (clone: CH/4, isotype: mouse IgG2a); others
were cross reactive with macaque (25, 26): anti-CD4-PE
(clone: L200, isotype: mouse IgG1,), anti-CD8-APC-CY7
(clone: rNase protection assay (RPA)-T8, isotype: mouse
IgG1,) and anti-CD69-FITC (clone: FN50, isotype: mouse
IgG1,) (BD PharMingen, San Diego, CA, USA). At 12 or 48 h,
PBMC were stained for surface expression of CD4, CD8,
CD25, and CD69 using the relevant mAbs. Cells were washed
twice with RPMI 1640 medium supplemented with 0.5% FBS
(wash medium). 1  106 cells were then incubated with
fluorochrome-tagged primary Ab in a total volume of 0.1 ml
for 30 min at 4°C. Cells were subsequently washed twice with
2 ml of wash medium to remove any unbound Ab and fixed
in 0.5 ml of 1% paraformaldehyde solution. Cells were then
analyzed by multicolor flow cytometry on a LSRII Analyzer
(Becton Dickinson, Franklin Lakes, NJ, USA). Data was
obtained using FACS DiVa acquisition software (Becton Dick-
inson) and analyzed using FlowJo6.1 (Tree Star) after appro-
priate gating to exclude dead cells and debris based on
forward scatter and side scatter. Fluorescent markers used
were APC (allophycocyanin), FITC (fluorescein isothiocya-
nate), PE (phycoerythrin), and APC-CY7 (allophycocyanin-
cyanine 7).
5-bromo-2-deoxyuridine (bromodeoxyuridine) labeling and
cell cycle analysis
Intracellular bromodeoxyuridine (BrdU) was measured using
a commercial assay (BrdU Flow Kit, BD Biosciences, Bedford,
MA, USA). Human PBMC were activated with anti-CD3/
CD28 in the absence or presence of filoviral peptides for 48 h.
Three hours before harvest, 10 M of BrdU was added to
each well. Cells were resuspended in 50 l of staining buffer
(PBS3.0% FBS). Fluorescent antibodies specific to detect
CD4 and CD8 were added. Cells were fixed, permeabilized,
and treated with DNase (30 g per tube) to expose incorpo-
rated BrdU. Intracellular BrdU was stained with anti-BrdU-
FITC Ab. Cells were washed and 20 l of 7-amino-actinomycin
D (7-AAD) solution was added for staining of total DNA. Cells
were resuspended in staining buffer and analyzed by flow
cytometry.
Apoptosis assays
PBMC were stained for surface expression of CD4 and CD8
using the relevant mAbs. Cells were washed twice with PBS,
resuspended in 0.1 ml Annexin V binding buffer (BD Bio-
sciences), and incubated with 5 l of FITC-conjugated An-
nexin V (BD Biosciences) and 10 l of propidium iodide (PI)
for 15 min at room temperature. The cells were immediately
analyzed by flow cytometry on a FACSCalibur (Becton Dick-
inson). Data were obtained using CellQuest acquisition soft-
ware (Becton Dickinson) and analyzed using FlowJo6.1 (Tree
Star, Ashland, OR, USA). Cells stained with Annexin V-FITC
alone and PI alone were used as controls.
Cytokine assays
Cell-free supernatants from PBMC cultures were collected
and analyzed using the Beadlyte Human 11-Plex Cytokine
Detection System (Upstate Biotechnology, Lake Placid, NY,
USA). The lyophilized mixed standard was resuspended in
cell culture medium and serially diluted. Samples or stan-
dards were incubated with the 11-Plex cytokine capture bead
suspension array in a 96-well filter plate for 2 h at room
temperature. The beads were washed and biotinylated re-
porter 11-plex antibodies were added for 1.5 h. Streptavi-
din-PE was then added to each well. After a 30 min incuba-
tion, the beads were washed and resuspended in assay buffer.
The median fluorescence intensity of 100 beads per cytokine
was read using a Luminex 100 Instrument. Concentrations
were interpolated from standard curves.
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Statistical analysis
All statistical analyses were performed using InStat 3 (Graph-
Pad Software). Data from all FACS assays (cell surface phe-
notype, BrdU incorporation, cell cycle analysis, apoptosis)
were first tested for normal distribution by the Kolmogorov
and Smirnov (K-S) test, then analyzed for significance using
ANOVA and Dunnett’s specialized multiple comparison test.
Cytokine assays were analyzed using Kruskal-Wallis nonpara-
metric ANOVA and the Dunn multiple comparison test.
Cytokine data were fitted on a sigmoidal dose-response curve.
RESULTS
We assessed the effect of synthetic 17mer peptides
corresponding to the candidate immunosuppressive
domain in filoviral glycoproteins. Human PBMC were
exposed for 48 h to either inactZEBOV or 40 M
filoviral peptides in the presence of anti-CD3/CD28.
Flow cytometric analysis revealed a significant decrease
in the percentage of cells positive for CD4 and CD8
after treatment with inactZEBOV or ZEBOV, SEBOV,
or MARV peptide, but not REBOV peptide (Fig. 1A, B).
ZEBOV peptide treatment also reduced the amount
of CD4 and CD8 expressed on the cell surface of
human PBMC. Exposure to ZEBOV peptide resulted in
a 3.5-fold reduction in cell surface expression of CD4
and a 4.2-fold reduction in the cell surface expression
of CD8 (CD4 expression with ZEBOV peptide, n5:
mean fluorescence intensity value for CD4
expressionsd of the mean, 96140; CD4 expression
without ZEBOV peptide, n5: 3,360145; P0.01;
CD8 expression with ZEBOV peptide, n5, mean flu-
orescence intensity value for CD8 expressionsd:
4,02575; CD8 expression without ZEBOV peptide,
n5: 17,027565; P0.01; Fig. 1C). A similar decrease
in CD4 and CD8 expression was observed on PBMC
treated with SEBOV or MARV peptides (data not
shown). No decrease in the expression levels of CD4 or
CD8 was observed with REBOV peptide treatment
(Fig. 1C).
ZEBOV peptide caused a significant decline in the
Figure 1. Depletion and inactivation of human T lymphocytes after exposure to inactivated filovirus or filoviral peptides. PBMC
were exposed to filoviral peptides, inactZEBOV, or to neither peptide nor virus for 48 h in the presence of anti-CD3/CD28. After
staining with antibodies to CD4 and CD8, cells were analyzed by flow cytometry. A) Dot plots of CD4 vs. CD8 lymphocytes
after activation with anti-CD3/CD28 alone (control), or anti-CD3/CD28 and ZEBOV peptide. Experiments were performed with
PBMC from 5 different donors; data from one representative donor are shown. Numbers in quadrants represent the percentages
of each subpopulation. B) Percentages of CD4 and CD8 lymphocyte subsets in PBMC following activation with
anti-CD3/CD28 antibodies alone or anti-CD3/CD28 and either filoviral peptides or inactZEBOV. Results are expressed as
percentage of total PBMC. Values represent mean  sd calculated from 5 different donors in each sample group. C)
Representative histogram showing cell surface expression of CD4 and CD8 markers on PBMC activated with anti-CD3/CD28
alone, or anti-CD3/CD28 and ZEBOV peptide. Numbers indicate the mean fluorescence intensity of CD4 or CD8 expression 
sd. Values were derived from 5 donors in each sample group. D) Absolute numbers of CD4 and CD8 T cells following
activation with anti-CD3/CD28 alone or anti-CD3/CD28 and filoviral peptide. Data represent mean  sd calculated from 5
different donors in each sample group. **P0.01 (relative to control samples; ANOVA and Dunnett’s test for multiple
comparisons).
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absolute numbers of both CD4 and CD8 T cells.
Exposure to ZEBOV peptide resulted in a 7.4-fold
decrease in the number of CD4 T cells and a 4.4-fold
decrease in the number of CD8 T cells (number of
CD4 T cells with ZEBOV peptide, n5: 5.51.8104;
number of CD4 T cells without ZEBOV peptide, n5:
40.63.7104; P0.01; number of CD8 T cells with
ZEBOV peptide, n5: 5.81.6104; number of CD8
T cells without ZEBOV peptide, n5: 25.42.6104;
P0.01; Fig. 1D). A similar decline in absolute T cell
numbers was also observed with SEBOV or MARV
peptide treatment. REBOV peptide exposure caused
no significant depletion of T cells (Fig. 1D).
To further characterize the immunosuppression ob-
served with the filoviral peptides, we evaluated the
phenotypic status of PBMC exposed to filoviral pep-
tides. The interleukin (IL) -2 receptor 	 chain (IL-2R)
is an essential component of high-affinity IL-2 recep-
tors. Whereas resting T cells do not express high-
affinity IL-2R, receptors are rapidly expressed on T cells
after activation with antigen or mitogens (27). The
interaction of IL-2 with IL-2R triggers proliferation.
IL-2R expression (CD25) was measured on human
PBMC activated with anti-CD3/CD28 in the presence
or absence of filoviral peptides (Fig. 2). ZEBOV peptide
treatment resulted in a reduction in the percentages of
Figure 2. Inactivation of human T lymphocytes after exposure to inactivated filovirus or filoviral peptides. PBMC were exposed
to filoviral peptides, inactZEBOV, or to neither peptide nor virus for 12 or 48 h in the presence of anti-CD3/CD28. After staining
with antibodies to CD4, CD8, CD25, and CD69, cells were analyzed by flow cytometry. A) Histograms represent expression of
activation markers in PBMC activated with anti-CD3/CD28 alone or anti-CD3/CD28 and ZEBOV peptide. Data were obtained
from 5 different donors; data from one representative donor are shown. Numbers in gates represent the percentages of CD25
or CD69 positive cells in the CD4 T or CD8 T cell subpopulations, respectively. B) Percentages of CD25 or CD69 positive cells
in CD4 and CD8 lymphocyte subsets following activation with anti-CD3/CD28 alone or anti-CD3/CD28 in the presence of
inactZEBOV or filoviral peptide. Results are expressed as percentages of CD4 or CD8 T cells. Values represent mean  sd
calculated from 5 different donors in each sample group. Data for CD69 expression were obtained 12 and 48 h after activation.
*P0.05; **P0.01 (relative to control samples; ANOVA and Dunnett’s test for multiple comparisons). C) Representative
histogram showing cell surface expression of CD25 and CD69 markers on PBMC activated with anti-CD3/CD28 alone, or
anti-CD3/CD28 and ZEBOV peptide. The mean fluorescence intensity is represented as a percentage of the maximum
expression. Data were obtained from 5 different donors; data from one representative donor are shown.
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CD25 cells in both CD4 and CD8 T cell popula-
tions (percentage of CD4 T cells treated with ZEBOV
peptide that are CD25, n5: 65.911.8%; without
ZEBOV peptide, n5: 93.93.0%; P0.01; percentage
of CD8 T cells treated with ZEBOV peptide that are
CD25, n5: 43.99.0%; without ZEBOV peptide,
n5: 77.99.2%; P0.01; Fig. 2A, B). Similar effects on
IL-2R expression were obtained in both CD4 and
CD8 T cells after exposure to SEBOV or MARV
peptides. No effect was observed with the nonpatho-
genic strain, REBOV (Fig. 2B). The mean fluorescent
intensity of CD25 expression was also decreased on
CD4 and CD8 T cells treated with ZEBOV peptide
but not REBOV peptide (Fig. 2C).
Lymphocyte activation in response to polyclonal mi-
togens, antibodies, or antigens is characterized by co-
ordinated surface expression of activation/adhesion
molecules. CD69 expression was used as a marker for T
cell activation (28) after exposure to anti-CD3/CD28 in
the presence of inactZEBOV or filoviral peptides. Ex-
posure for 48 h to ZEBOV peptide resulted in a
decrease in the percentages of CD69 cells in both
CD4 and CD8 T cell populations (percentage of
CD4 T cells treated with ZEBOV that are CD69,
n5: 69.43.4%; without ZEBOV, n5: 80.86.4%;
P0.05; percentage of CD8 T cells treated with
ZEBOV that are CD69, n5: 67.99.6%; without
ZEBOV, n5: 84.96.9%; P0.05; Fig. 2B). Exposure
for 48 h to SEBOV or MARV peptides or inactZEBOV
resulted in a significant reduction in the percentage of
CD69 CD8 T cells; a trend toward reduction was
observed in CD69 CD4 T cells that did not achieve
statistical significance (Fig. 2B). Exposure for 12 h to
ZEBOV, SEBOV, or MARV peptide resulted in a signif-
icant reduction in percentages of both CD69 CD4 T
cells and CD69 CD8 T cells (Fig. 2A, B). No effect
was observed with REBOV peptide at either 12 or 48 h
(Fig. 2B). The mean fluorescent intensity of CD69
expression was also decreased on CD4 and CD8 T
cells treated for 12 h with ZEBOV peptide but not
REBOV peptide (Fig. 2C).
Proliferative responses of T lymphocytes exposed to
filoviral peptides were assessed by flow cytometric mea-
surement of BrdU incorporation. Human PBMC were
treated with anti-CD3/CD28 in the presence or absence
of ZEBOV peptide or REBOV peptide for 48 h. BrdU
was added for the final 3 h of culture. ZEBOV peptide
treatment resulted in decreased BrdU labeling of
CD4 and CD8 T cells (percentage of BrdU labeled
CD4 cells treated with ZEBOV peptide, n5:
3.90.6%; without ZEBOV peptide, n5: 14.42.3%;
P0.01; percentage of BrdU labeled CD8 cells
treated with ZEBOV peptide, n5: 4.81.8%; without
ZEBOV peptide, n5: 9.40.9%; P0.01; Fig. 3A, B).
No significant change in BrdU labeling was observed
with REBOV peptide (Fig. 3A, B). Cell cycle analysis of
PBMC treated with ZEBOV peptide and anti-CD3/
CD28 revealed an increase in the hypodiploid popula-
tion together with decreased cell cycle progression
(Fig. 3C). ZEBOV-peptide treated PBMC showed an
8.8-fold increase in the number of cells with hypodip-
loid DNA content (percentage of peptide-treated cells
with hypodiploid DNA, n5: 22.02.2%; untreated
cells, n5: 2.50.1%; P0.01) consistent with an in-
duction in apoptosis (29) (Fig. 3C). A 3.5-fold decrease
in the percentage of cells in the S phase was observed
with ZEBOV peptide treatment (percentage of peptide-
treated cells in S phase, n5: 8.00.5%; untreated
cells, n5: 28.12.4%; P0.01), suggesting a decrease
in the numbers of actively cycling cells. No change in
the cycling pattern was observed with PBMC treated
with REBOV peptide (Fig. 3C). These results suggest
that filoviral peptide treatment may reduce the num-
bers of T cells by depression of proliferative responses
as well as by induction of apoptosis.
Profound lymphopenia and lymphoid depletion due
to apoptosis are characteristic features of fatal filoviral
infections (7). Apoptosis may be independent of viral
replication (30, 31). Treatment of human PBMC with
inactZEBOV for 48 h in the presence of anti-CD3/
CD28 resulted in a 2.9-fold increase in apoptotic cells in
the CD4 population and a 2.1-fold increase in the
CD8 population (percentage of Annexin V PI–
CD4 exposed to inactZEBOV, n5: 41.03.3%; un-
treated cells, n5: 14.32.3%, P0.01; percentage of
Annexin V PI– CD8 exposed to inactZEBOV, n5:
30.11.9%; untreated cells, n5: 14.22.1%, P0.01;
Fig. 4A). ZEBOV peptide treatment also resulted in
induction of apoptosis in both CD4 and CD8 T cells
(Fig. 4B–D). Human PBMC were exposed to ZEBOV
peptide in the presence of anti-CD3/CD28 for 12 h and
subjected to flow cytometric analysis. Viable PBMC
were gated according to forward scatter (FSC) and side
scatter (SSC) profile (R1 gate, Fig. 4B). Live (R1) cells
were further gated on CD4 cells according to CD4
expression and FSC and on CD8 cells according to
CD8 expression and FSC (R5 gate; Fig. 4C, D). The
percentages of apoptotic cells in CD4 and CD8 T
cell populations were determined by Annexin V/PI
staining. Cells positive for Annexin V and negative for
PI were considered apoptotic (Fig. 4C, D). ZEBOV
peptide treatment resulted in a 3.6-fold increase in
apoptotic CD4 cells and a 2.0-fold increase in apopto-
tic CD8 cells (percentage of Annexin V PI– CD4
treated with ZEBOV peptide, n5: 43.65.8%; un-
treated cells, n5: 12.21.9%; P0.01; percentage of
Annexin V PI– CD8 treated with ZEBOV peptide,
n5: 29.73.7%; untreated cells, n5: 14.92.1%;
P0.01; Fig. 4C, D). Effects were similar with human
PBMC exposed to SEBOV or MARV peptides (Fig. 4E).
No significant induction of apoptosis was observed after
treatment with REBOV peptide (Fig. 4B, C–E). Taken
together, these data implicate apoptosis in T cell deple-
tion after filoviral peptide exposure and are consistent
with the observation that whereas ZEBOV, SEBOV, and
MARV are pathogenic for humans, REBOV is not.
Cytokines and chemokines play important roles in
immunopathological processes and normal immune
response. In addition, there is evidence for the involve-
ment of inflammatory mediators in the pathogenesis of
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EBOV infection from previous studies wherein infected
individuals had elevated levels of circulating TNF-	,
IL1-
, IL-6, MIP1-	, and MCP-1 (10, 11, 32). We studied
the influence of ZEBOV peptide on cytokine produc-
tion by stimulated human PBMC. At 40 M concentra-
tion, ZEBOV peptide suppressed anti-CD3/CD28-in-
duced production of the Th1 cytokines IFN- (P0.05;
relative to control values) and IL-12p40 (P0.05; rela-
tive to control values) (Fig. 5A). ZEBOV peptide also
suppressed production of the proliferative and differ-
entiation factor IL-2 (P0.05; relative to control values)
and induced a dose-dependent reduction in TNF-	
(P0.05; relative to control values), IL-1
 (P0.01;
relative to control values), and MCP-1 (P0.01; relative
to control values) (Fig. 5B). There was no effect on
MIP1-	 (Fig. 5B). ZEBOV peptide effects on Th2
cytokines were less consistent. ZEBOV peptide expo-
sure resulted in an increase of IL-10 (P0.01; relative to
control values); a trend toward decrease was observed
with IL-4; no pattern was observed with IL-6 (Fig. 5C).
Cytokine data were fitted on a sigmoidal dose-response
curve (variable slope) with R2 values ranging from
0.8885 to 0.9748 (IL-2, IFN-, IL-12, TNF-	, and IL-1
).
The R2 value for IL-10 was 0.7922. No effects were
observed when human PBMC were exposed to REBOV
peptide (Fig. 5A–C).
The observation that REBOV peptide had no effect
on human PBMC in multiple assays was consistent with
its lack of pathogenicity in humans. Given, however,
that REBOV is pathogenic in monkeys, we predicted
that an immunosuppressive REBOV effect would be
seen with monkey PBMC. To test this hypothesis, rhesus
macaque (Macaca mulatta) PBMC were incubated with
REBOV peptide in the presence of anti-CD3 epsilon
Ab. ZEBOV is pathogenic in monkeys as well as apes
and humans; thus, ZEBOV peptide was used as a
positive control. Significant depletion of CD4 T cells
and CD8 T cells was observed with exposure to
REBOV peptide or ZEBOV peptide (Fig. 6A, B).
REBOV peptide exposure for 48 h resulted in a 4.5-fold
Figure 3. Defective proliferation and cell cycle progression in human T lymphocytes after exposure to filoviral peptides. PBMC
were exposed to ZEBOV peptide, REBOV peptide, or no peptide for 48 h in the presence of anti-CD3/CD28. After staining with
antibodies to CD4, CD8, and BrdU, cells were analyzed by flow cytometry. A) Dot plots of PBMC activated with anti-CD3/CD28
alone or anti-CD3/CD28 and ZEBOV peptide. Data were obtained from 5 different donors; data from one representative donor
are shown. Numbers in quadrants represent the percentages of each subpopulation. B) Percentage of BrdU cells in CD4 and
CD8 lymphocyte subsets following activation with anti-CD3/CD28 alone or anti-CD3/CD28 and either ZEBOV peptide or
REBOV peptide. Results are expressed as percentages of total PBMC. Values represent mean sd for 5 different donors in each
sample group. C) Cell cycle analysis of PBMC activated with anti-CD3/CD28 or anti-CD3/CD28 and either ZEBOV peptide or
REBOV peptide. Cells were stained with 7-AAD and analyzed by flow cytometry. Percentages of cells in G1, S, G2, and
hypodiploid phases of the cell cycle are represented as a table. Values indicate mean  sd calculated from 5 different donors
in each sample group. *P  0.01 (relative to control samples; ANOVA and Dunnett’s test for multiple comparisons).
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decrease in the number of CD4 T cells and a 4.6-fold
decrease in the number of CD8 T cells (number of
CD4 T cells with REBOV peptide, n5: 4.80.7104;
number of CD8 T cells without REBOV peptide, n5:
26.62.7104; P0.01; number of CD8 T cells with
REBOV peptide, n5: 2.30.4104; number of CD8
T cells without REBOV peptide, n5: 14.71.2104;
P0.01; Fig. 6B). REBOV peptide exposure resulted in
a decrease in the percentages of CD69 cells in both
CD4 and CD8 T cell populations (percentage of
CD4 rhesus T cells treated with REBOV peptide that
are CD69, n5: 63.61.9%; without REBOV peptide,
n5: 89.12.6%; P0.01; percentage of CD8 rhesus
T cells treated with REBOV peptide that are CD69,
n5: 60.73.1%; without REBOV peptide, n5:
84.32.7%; P0.01; Fig. 6D). The mean fluorescent
intensity of CD69 expression was also decreased in
CD4 and CD8 T cells treated with REBOV peptide
(Fig. 6E). REBOV treatment for 12 h resulted in a
3.1-fold increase in apoptotic CD4 cells and a 2.6-fold
increase in apoptotic CD8 cells (percentage of An-
nexin V PI-rhesus CD4 treated with REBOV pep-
tide, n5: 46.02.1%; untreated cells, n5:
14.03.0%; P0.01; percentage of Annexin V PI–
CD8 treated with REBOV peptide, n5: 31.83.3%;
untreated cells, n5: 12.33.0%; P0.01; Fig. 7A).
Decreased T cell activation and increased apoptosis
were also observed with ZEBOV peptide and inactZE-
BOV (Fig. 6C–E, Fig. 7A). Both ZEBOV peptide and
REBOV peptide at a dose of 40 M cause a significant
Figure 4. Filoviral peptide exposure induces human T cell apoptosis. PBMC were exposed to filoviral peptides, inactZEBOV, or
to neither peptide nor virus in the presence of anti-CD3/CD28. After staining with antibodies to CD4, CD8, AnnexinV-FITC
(marker for apoptosis) and PI (marker for apoptosis or necrosis), cells were analyzed by flow cytometry. A) Percentages of
AnnexinV-FITC PI– cells in gated CD4 or CD8 cells after treatment with anti-CD3/CD28 antibodies alone or
anti-CD3/CD28 and inactZEBOV for 48 h. Values represent mean  sd calculated from 5 different donors in each sample
group. B) Strategy for gating PBMC. Viable PBMC were gated according to forward scatter (FSC) and side scatter (SSC) profile
(R1 gate). C) Live (R1) cells were further gated according to CD4 expression and FSC (R5). Dot plots of AnnexinV-FITC and
PI fluorescence on gated CD4 cells. D) Live (R1) cells were further gated according to CD8 expression and FSC (R5). Dot plots
of AnnexinV-FITC and PI fluorescence on gated CD8 cells. C, D) Numbers in quadrants represent the percentages of each
subpopulation. Experiments were performed with PBMC from 5 different donors; results obtained from one donor are shown.
E) Percentages of AnnexinV-FITC PI– cells in gated CD4 or CD8 cells after treatment with anti-CD3/CD28 antibodies
alone or anti-CD3/CD28 and filoviral peptide for 12 h. Values represent mean  sd calculated from 5 different donors in each
sample group. **P  0.01 (relative to control samples; ANOVA and Dunnett’s test for multiple comparisons).
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decrease in Th1 (IFN- and IL-12p40; P0.05) and
inflammatory cytokines (TNF-	 and IL1-
; P0.05)
(Fig. 7B) compared with control values. Levels of IL-8
and MIP1-	 did not alter with exposure to either
peptide (Fig. 7B).
DISCUSSION
Ebola and Marburg viruses can cause hemorrhagic
fever (HF) outbreaks with high mortality in primates.
Whereas MARV, ZEBOV and SEBOV are pathogenic in
humans, apes, and monkeys, REBOV is pathogenic only
in monkeys. Early immunosuppression may contribute
to pathogenesis by facilitating viral replication. The
filoviral proteins VP35 and VP24 have immunomodu-
latory effects. VP35 inhibits induction of IFN-	 and -

by blocking phosphorylation and nuclear translocation
of IFN regulatory factor-3 (4, 33). ZEBOV VP24 inter-
acts with karyopherin 	1, the nuclear localization signal
receptor for PY-STAT1 (34). Active virus replication is
prerequisite for the immunosuppressive effects of VP35
and VP24. In contrast, the immunosuppressive effects
we have observed with filoviral GP sequences are inde-
pendent of viral replication.
The 17mer filoviral peptides ZEBOV, SEBOV, or
MARV had a strong immunosuppressive influence on
anti-CD3/CD28-activated human PBMC. Furthermore,
activated CD4 and CD8 T cells failed to up-regulate
activation markers on their surface and exhibited re-
duced cell cycle progression. CD4 and CD8 T cell
dysfunction may stem from immune inactivation after
direct contact with the peptide. Alternatively, the effect
may be the indirect result of inadequate stimulation by
the antigen-presenting cells. In vitro studies of ZEBOV
have revealed suppression of immune responses within
infected monocyte/macrophages and endothelial cells
(35, 36). Dendritic cells infected with ZEBOV are
functionally impaired and only poorly stimulate T cells
(37, 38). IFN-	/
 production has been shown to
influence dendritic cell functions. VP35 protein of
ZEBOV suppresses the induction of IFN-	/
 and
may indirectly contribute to inhibition of dendritic
cell functions (33).
T cells do not support filoviral replication (7). The
observation that inactZEBOV can induce T cell apopto-
sis in PBMC cultures is consistent with earlier studies
Figure 5. Exposure of human PBMC to ZEBOV peptide results in decreased release of IFN-, IL-2, IL-12p40, TNF-	, IL-1
, and
MCP-1, and increased release of IL-10. PBMC were exposed to 1, 20, or 40 M of ZEBOV peptide, REBOV peptide, or no
peptide for 48 h in the presence of anti-CD3/CD28. Cytokines were assayed in cell supernatant using Luminex technology.
Results indicate mean concentration (pg/ml)  sd. Values were obtained from 5 different donors in each sample group. *P 
0.05; **P  0.01 (relative to control samples; Kruskal-Wallis nonparametric ANOVA with Dunn’s multiple comparison test).
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indicating that virus replication is not a prerequisite for
T cell apoptosis (30, 31). Potential mechanisms for T
cell apoptosis in PBMC cultures treated with filoviral
peptides include direct interaction of peptides with the
cell surface or indirect effects mediated by soluble
factors released from monocytes exposed to these pep-
tides. Studies of purified human CD4 and CD8 T
cells indicate that ZEBOV peptide alone is sufficient to
induce activation and cell death in either population. It
is conceivable that direct and indirect mechanisms may
both be implicated in T cell apoptosis.
We examined the influence of ZEBOV peptide on
Th1- and Th2-related cytokine production by stimu-
lated PBMCs using Luminex technology. Whereas T
helper type 1 cells predominantly produce IFN-, T
helper type 2 cells secrete IL-4, IL-5, and IL-10.
IL-12, a cytokine produced by monocytes/macro-
phages, enhances cell-mediated immunity (39, 40). IL-10
is mainly produced by monocytes/macrophages and T
cells; it inhibits activation of T-helper lymphocytes either
directly (41) or by suppressing activation of antigen
presenting cells (42). High plasma levels of IL-10 are
reported in filovirus-infected patients with a fatal outcome
(11). Our data show that the 17mer ZEBOV peptide
suppresses expression of the type 1 cytokines IL-12 and
IFN- while enhancing expression of the type 2 cytokine
IL-10. Enhanced expression of IL-10 and reduced expres-
sion of IL-12 may imbalance Th1- and Th2-related cyto-
Figure 6. Exposure of rhesus macaque PBMC to REBOV peptide results in depletion and inactivation of CD4 and CD8 T
cells. Rhesus PBMC were exposed to ZEBOV peptide, REBOV peptide, or no peptide for 48 h in the presence of anti-human
CD3ε. A) Dot plots of CD4 vs. CD8 lymphocytes in activated PBMC exposed to ZEBOV peptide or REBOV peptide. Experiments
were performed with PBMC from 5 different donors; results obtained from one donor are shown. Numbers in quadrants
represent the percentages of each subpopulation. B) Absolute numbers of CD4 and CD8 T cells following activation of
PBMC with anti-CD3ε alone or anti-CD3ε and either ZEBOV peptide or REBOV peptide. Data represent mean  sd calculated
from 5 macaques in each sample group. C) Percentages of CD4 and CD8 lymphocyte subsets in PBMC following activation
with anti-CD3ε Ab alone or anti-CD3ε and either ZEBOV peptide or REBOV peptide. Results are expressed as percentages of
total PBMC. Values represent mean  sd calculated from 5 macaques in each sample group. D) Percentages of CD69CD4
and CD69CD8 subsets in PBMC following activation with anti-CD3ε or anti-CD3ε and either ZEBOV peptide or REBOV
peptide. Results are expressed as percentages of CD4 or CD8 T cells. Values represent mean  sd calculated from 5
macaques in each sample group. *P  0.05; **P  0.01 (relative to control samples; ANOVA and Dunnett’s test for multiple
comparisons). E) Representative histogram showing cell surface expression of CD69 markers on rhesus PBMC activated with
anti-CD3ε or anti-CD3ε and either ZEBOV peptide or REBOV peptide. Mean fluorescence intensity is represented as a
percentage of the maximum expression. Data were obtained from 5 different donors; data from one representative donor are
shown.
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kine production and suppress cell-mediated immunity.
Haraguchi et al. (19) have demonstrated that CKS-17, a
retroviral peptide, acts directly on monocytes/macro-
phages and differentially modulates the production of
IL-10 and IL-12. Furthermore, a neutralizing anti-human
IL-10 monoclonal antibody (mAb) blocks the peptide-
mediated inhibition of IFN-, supporting the hypothesis
that inhibition of IFN- production may be secondary to
an increase in IL-10 and depression in IL-12 levels pro-
duced by the retroviral peptide. Similar cytokine-medi-
ated cross-regulation may be implicated in filoviral immu-
nosuppression.
Proinflammatory cytokines and chemokines play a vital
role in one of the earliest phases of the host resistance to
viral and microbial infections by participating in various
cellular and inflammatory processes. In our study, 17mer
filoviral peptides decreased secretion in PBMC cultures of
proinflammatory cytokines TNF	 and IL-1
 and chemo-
kine MCP-1. These defective inflammatory responses may
be associated with impaired T cell activation observed in
peptide-treated lymphocytes. Nonfatal ZEBOV infection
is associated with early inflammatory responses (32). The
observed peptide-mediated cytokine inhibition suggests
that filoviral transmembrane glycoprotein may be in-
volved in suppressing the onset of early inflammatory
responses that are crucial for controlling viral spread in
filoviral infections.
All African EBOV subtypes (ZEBOV, SEBOV, and
Ivory Coast) cause a severe hemorrhagic disease in
humans and nonhuman primates with extraordinarily
high fatality rates. The fourth subtype, REBOV, initially
isolated from cynomolgus monkeys, is nonpathogenic
in humans and appears to be a lethal pathogen only for
nonhuman primates (2). Exposure of human PBMC to
REBOV peptides had no effect on markers of CD4 or
CD8 activation, viability, or cytokine levels in cell
supernatants. Whereas human PBMC were sensitive to
ZEBOV but not REBOV, monkey PBMC were sensitive
to both ZEBOV and REBOV. These findings demon-
strate that strain-specific differences in peptide se-
quence determine immunological effects on PBMC in
vitro and correlate with the pathogenic potential of
Figure 7. Exposure of rhesus macaque PBMC to REBOV peptide results in apoptosis of CD4 and CD8 T cells and in
decreased release of IFN- and IL-12p40. A) PBMC were exposed to filoviral peptide, inactZEBOV, or to neither peptide nor
virus in the presence of anti-CD3ε. After staining with antibodies to CD4, CD8, AnnexinV-FITC (marker for apoptosis), and PI
(marker for apoptosis or necrosis) cells were analyzed by flow cytometry. Percentages of AnnexinV-FITC PI– cells in gated
CD4 or CD8 T cells after treatment with anti-CD3ε alone or anti-CD3ε and inactZEBOV, ZEBOV peptide, or REBOV
peptide. Values represent mean  sd calculated from 5 macaques in each sample group. *P  0.01 relative to control samples
(ANOVA and Dunnett’s test for multiple comparisons). B) PBMC were exposed for 48 h to 1, 20, or 40 M of ZEBOV peptide,
REBOV peptide or no peptide in the presence of anti-CD3ε. Cytokines in cell supernatants were assayed by flow cytometry
(Luminex). Results indicate mean concentration (pg/ml) sd. *P  0.05; **P  0.01 (relative to control samples;
Kruskal-Wallis nonparametric ANOVA with Dunn’s multiple comparison test).
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ZEBOV, SEBOV, and MARV viruses vs. REBOV virus in
human and nonhuman primates (12).
The rapidly progressing high-fatality hemorrhagic
fever associated with EBOV and MARV infections is
accompanied by profound immunosuppression and
vascular dysfunction. Several factors likely contribute to
the severity of disease. These viruses quickly replicate
and cause cytotoxicity in a wide range of cells and
tissues within the body, and the viral glycoprotein
(particularly the mucin-like domain) has been impli-
cated in this cytotoxicity (12). Recent studies have also
demonstrated an immunosuppressive effect of the viral
VP35 protein in inhibiting IFN regulatory factor 3
(IRF-3) activation and induction of IFN-	 and -
 as well
as other antiviral responses (33, 43). Our findings show
that in addition to contributing to HF pathogenicity
through cytotoxicity, filoviral glycoproteins also have a
potent immunosuppressive effect. The 17 amino acid
motif described here dysregulates Th1 and Th2 re-
sponses and depletes CD4 and CD8 T-cells through
apoptosis. Focused investigation of interactions be-
tween filoviral glycoproteins and the host immune
system may enable development of specific strategies to
reduce the extreme morbidity and mortality associated
with HF due to EBOV and MARV infections.
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Filovirus
ZEBOV strain KIKWIT (1995) ILNRKAIDFLLQRWGGTC
ZEBOV strain GABON (1994) ILNRKAIDFLLQRWGGTC
ZEBOV strain MAYINGA (1976) ILNRKAIDFLLQRWGGTC
ZEBOV strain EKRON (1976) ILNRKAIDFLLQRWGGTC
CIEBOV strain IVORY COAST (1994) ILNRKAIDFLLQRWGGTC
REBOV strain RESTON (1989)        LLNRKAIDFLLQRWGGTC
REBOV Strain SIENA (1992)         LLNRKAIDFLLQRWGGTC
SEBOV strain BONIFACE (1976)      ILNRKAIDFLLRRWGGTC
SEBOV strain MALEO (1979)         ILNRKAIDFLLRRWGGTC
MARV strain OZOLIN (1975) LINRHAIDFLLTRWGGTC
MARV strain POPP (1967) LINRHAIDFLLTRWGGTC
MARV strain MUSOKE (1980) LINRHAIDFLLTRWGGTC
MARV strain RAVN (1987) LINRHAIDFLLTRWGGTC





HERV_K                    MNNRLALDYLLAEQGGVC
Friend MLV                LQNRRGLDLLFLKEGGLC
Avian Sarcoma Virus       LQNRAAIDFLLLAHGHGC
Zebrafish ERV             IQNRLALDMLLSERGGVC
**  :* *:      *
Blue residues: Species characteristics residues
Red residues: Particular residues change for the specie
* Conserved residue
: Conserved properties 
Sequence of the 17AA Immunosuppressive Domain
Ebola-like 
virus
Marburg-like 
virus
